Loading...
Plasmodial kinase inhibitors: License to cure?
Cabrera, D.G Horatscheck, A Wilson, C.R Basarab, G Eyermann, C.J Chibale, K
Cabrera, D.G
Horatscheck, A
Wilson, C.R
Basarab, G
Eyermann, C.J
Chibale, K
Citations
Altmetric:
Abstract
Advances in the genetics, function, and stage-specificity of Plasmodium kinases has driven robust efforts to identify targets for the design of antimalarial therapies. Reverse genomics following phenotypic screening against Plasmodia or related parasites has uncovered vulnerable kinase targets including PI4K, PKG, and GSK-3, an approach bolstered by access to human disease-directed kinase libraries. Alternatively, screening compound libraries against Plasmodium kinases has successfully led to inhibitors with antiplasmodial activity. As with other therapeutic areas, optimizing compound ADMET and PK properties in parallel with target inhibitory potency and whole cell activity becomes paramount toward advancing compounds as clinical candidates. These and other considerations will be discussed in the context of progress achieved toward deriving important, novel mode-of-action kinase-inhibiting antimalarial medicines.
Description
Date
2018-09-27
Journal Title
Journal ISSN
Volume Title
Publisher
ACS Publications
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Citation
Cabrera DG, Horatscheck A, Wilson CR, Basarab G, Eyermann CJ, Chibale K. Plasmodial Kinase Inhibitors: License to Cure? Journal of Medicinal Chemistry. 2018;61(18):8061-77. DOI: 10.1021/acs.jmedchem.8b00329.